摘要
目的观察神经妥乐平联合普瑞巴林对血液透析患者合并带状疱疹后遗神经痛的临床疗效及安全性,探讨血液透析合并带状疱疹后遗神经痛的临床治疗方法。方法选择该院血液透析中心2014年3月至2018年8月维持性血液透析合并带状疱疹后遗神经痛的患者38例,所有患者除维持性血液透析及一般治疗外,18例对照组患者采用普瑞巴林胶囊治疗,20例观察组患者在对照组基础上加用神经妥乐平注射液治疗,两组患者均接受8周的治疗,观察血液透析患者带状疱疹后神经痛症状缓解的有效率等指标。结果治疗组患者临床总有效率(90.00%)明显高于对照组(72.22%),差异有统计学意义(P<0.05);治疗组患者治疗后疼痛视觉模拟评分(VAS)、汉密尔顿抑郁量表(HAMD)评分和匹兹堡睡眠质量指数(PSQI)评分均明显低于对照组及治疗前,差异有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论神经妥乐平联合普瑞巴林治疗维持性血液透析合并带状疱疹后神经痛患者可有效缓解疼痛症状,提高患者睡眠质量,改善患者抑郁状态,且不增加不良反应发生风险。
Objective To observe the clinical efficacy and safety of Neurotropin assisting Pregabalin in the treatment of secondary post-herpetic neuralgia in uremic patients underwent maintenance hemodialysis.Methods A total of 38 patients with post-herpetic neuralgia underwent maintenance hemodialysis were divided into the control group and the treatment group.The control group(n=18)was given loratadine Pregabalin.The treatment group(n=20)was additionally given Neurotropin on the basis of the control group.Both groups received treatment for 8 weeks.The clinical efficacy was compared between the two groups.Results The total effective rate of the treatment group(90.00%)was significantly higher than that of the control group(72.22%),the difference was statistical significant(P<0.05);visual analogue scale(VAS)score,Hamilton depression scale(HAMD)score and pittsburgh sleep quality index(PSQI)score of the treatment group after treatment were significantly lower than those of the control group and before treatment,the difference was statistical significant(P<0.05).There was no significant difference in the incidence of adverse events between the two groups(P>0.05).Conclusion Neurotropin assisting Pregabalin in the treatment of secondary post-herpetic neuralgia in patients with maintenance hemodialysis can efficiently relieve the pain symptoms,improve sleep quality,and not increase the risk of adverse events.
作者
熊艳
徐艳梅
许传文
XIONG Yan;XU Yanmei;XU Chuanwen(Wuhan Fourth Hospital/Puai Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430000,China)
出处
《重庆医学》
CAS
2019年第19期3253-3256,共4页
Chongqing medicine
基金
湖北省武汉市卫生和计划生育委员会课题(WZ15D10)
